We read with great interest the article by Greiner-Mai et al. [1] describing telomere biology disorder (TBD)-associated childhood interstitial lung disease (chILD). Their cohort, although small, highlights the severity of this condition: 7 of 10 children required long-term oxygen therapy, 3 underwent hematopoietic stem cell or bone marrow transplantation, and 4 died during follow-up. These findings suggest that TBD-associated chILD should be viewed not only as a rare genetic diagnosis, but also as a high-risk multisystem respiratory disease.

A practical implication is the need for earlier bedside suspicion. Current chILD diagnostic approaches emphasize stepwise evaluation, expert-center referral, imaging, and genetic testing when appropriate [2]. In this pathway, TBD evaluation should be considered early when unexplained interstitial lung disease (ILD) occurs with extrapulmonary red flags, including cytopenia or bone marrow failure, liver disease, poor growth, mucocutaneous findings, recurrent infections, vascular abnormalities, or a family history of pulmonary fibrosis, marrow failure, liver disease, early graying, or unexplained early death. These features reflect the multisystem biology of TBDs, which may involve pulmonary, hematologic, hepatic, vascular, and cancer-predisposition phenotypes [3].

This recognition has therapeutic relevance. Greiner-Mai et al. [1] noted severe diffusion impairment and progressive respiratory disease despite intensive therapy. Adult data suggest that short leukocyte telomere length may identify patients with idiopathic pulmonary fibrosis who are vulnerable to poor outcomes with immunosuppression, although direct pediatric extrapolation should be cautious [4]. Conversely, pediatric data from InPedILD support the feasibility of weight-based nintedanib use in children with fibrosing ILD, but telomere-specific pediatric efficacy remains uncertain [5].

Therefore, early recognition of TBD-associated chILD should trigger multidisciplinary planning among pulmonology, genetics, hematology, transplant, and critical care teams before prolonged empiric immunosuppression or late transplant referral.